On July 21, CSL Behring and Ferring Pharmaceuticals announced the recall of multiple lots of Stimate (desmopressin) in the United States, as part of a global recall. This troubling announcement has raised many questions on the part of national and international patient organizations and community members. Today, HFA and NHF have submitted a letter to CSL Behring and Ferring requesting information about how this serious situation occurred and how they will ensure patient safety going forward. This is only the first step in what we expect to be continuing communications with the two companies about this situation. HFA and NHF will keep the bleeding disorders community informed as information is gathered.

Read the recall notice from CSL Behring & Ferring Pharmaceuticals here.

Read the joint letter from HFA and NHF to CSL Behring & Ferring Pharmaceuticals here.

Please note that NHF and HFA do not recommend, endorse or make any representation about the efficacy, appropriateness or suitability of any specific products, treatments, or opinions. If you have any questions or concerns about your medical treatment, including your possible exposure to recalled product, please consult your physician.

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.